Viking Therapeutics VKTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's financing cash flow?
- Viking Therapeutics (VKTX) reported financing cash flow of $12.08M in Q1 2026.
- How has Viking Therapeutics's financing cash flow changed year-over-year?
- Viking Therapeutics's financing cash flow increased by 3360.5% year-over-year, from $349K to $12.08M.
- What is the long-term trend for Viking Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Viking Therapeutics's financing cash flow has grown at a 80.9% compound annual growth rate (CAGR), from $7.14M to $76.44M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.